Predict your next investment

Corporation
HEALTHCARE | Disease Diagnosis
grail.com

See what CB Insights has to offer

Founded Year

2015

Stage

Acquired | Acquired

Total Raised

$2.005B

Valuation

$0000 

About GRAIL

GRAIL combines high-intensity sequencing, computer science, and large population-scale clinical studies to develop a blood test for early-stage cancer detection.On September 21st, 2020, GRAIL was acquired by Illumina at a valuation of $8B. At the time of the acquisition, Illumina, a prior investor in Grail owned 14.5% of the company’s outstanding shares which made the effective purchase price for Grail closer to $7 billion.

GRAIL Headquarter Location

1525 O'Brien Drive

Menlo Park, California, 94025,

United States

650-542-0372

Latest GRAIL News

Illumina (ILMN) Announces Preliminary Q4 Sales, Issues '22 View

Jan 12, 2022

Illumina's (ILMN) preliminary fourth-quarter results, latest partnership deals and a robust pipeline of technologies instill investor optimism. This story originally appeared on Zacks Illumina, Inc. ILMN recently announced preliminary fourth-quarter and full-year 2021 revenues along with 2022 top-line guidance at the 2022 J.P. Morgan Healthcare Conference. The company also discussed its latest partnerships and product pipelines, defining its long-term growth opportunities. - Zacks Preliminary Q4 & ’21 Results Illumina reported preliminary consolidated fourth-quarter revenues of around $1.19 billion, up 25% year over year on record revenue growth across instruments and consumables. The Zacks Consensus Estimate for its fourth-quarter revenues is pegged at $1.09 billion. In addition, the company reported preliminary fiscal year 2021 consolidated revenues of around $4.517 billion, up 39% from 2020. This upside was driven by record revenues in all regions and the highest number of shipments. The Zacks Consensus Estimate for Illumina’s 2021 revenues is pegged at $4.42 billion, suggesting a 36.4% rise from the year-ago reported figure. 2022 Outlook Illumina projects consolidated revenues of $5.15-$5.24 billion for 2022, indicating growth in the range of 14-16% year over year as sequencing awareness, demand and adoption expand. The Zacks Consensus Estimate for the same is pegged at $4.88 billion, suggesting a 10.5% rise from the year-ago reported figure. New Collaboration Deals Illumina has entered into partnership agreements with Agendia and Boehringer Ingelheim to advance the development of precision diagnosis and treatment medicines for advanced cancer patients. The company also announced a collaboration with Optum -- a leading health services innovation company -- to bolster the adoption of genomics into clinical practice. Both Illumina and Optum are conducting studies to identify, validate and demonstrate the efficacy of genomics-based testing through the newly-developed Optum Evidence Engine. Image Source: Zacks Investment Research Illumina has entered into another collaboration deal with SomaLogic to co-develop an end-to-end solution utilizing the largest protein target set of more than 10,000 proteins and the high-throughput capabilities of its existing and future next-generation sequencing platforms. Meanwhile, the company’s newly-established partnership with Nashville Biosciences -- a wholly-owned subsidiary of Vanderbilt University Medical Center -- is anticipated to drive enhanced medicine development. It is worth noting that these innovative partnerships position Illumina to advance genomic uptake and enhance human health globally. Update on GRAIL Post the acquisition of GRAIL on Aug 18, 2021, Illumina has two reportable segments-- Core Illumina and GRAIL. In 2021, GRAIL launched Galleri, the first multi-cancer early detection blood test to be clinically validated in a screening population. At present, GRAIL is collaborating with multiple healthcare partners to ensure the rapid and widespread availability of this test. With eight clinical studies currently underway or planned, GRAIL's comprehensive evidence generation for Galleri is largely regarded as one the largest clinical genomics programs ever conducted. GRAIL has also announced a new collaboration with Premier's PINC AI to enhance its clinical decision support technology. This collaboration will aid clinicians in identifying patients with an elevated risk of cancer who are likely to benefit from the Galleri test. Robust Pipeline Hold Potential Building on its more than 20-year track record of innovation, Illumina is currently focused on developing breakthrough chemistry, codenamed Chemistry X, that delivers two times faster cycle times, two times longer readings and three times greater accuracy. Per management, the breakthrough Chemistry X will serve as the foundation for all future platforms. Illumina is set to launch new bioinformatics technology on its DRAGEN platform in the first quarter, which can support DNA, RNA, methylation and a Bayesian theory approach to machine learning allowing for the most rapid, cost-effective and accurate analysis of any platform. Furthermore, the company unveiled novel patented technologies for a highly accurate and cost-effective long read workflow, codenamed Infinity, that will produce contiguous data up to 10Kb in length to address the genome’s final edge cases. Management believes that the Infinity long-read technology will enable researchers to boost access to the remaining 5% of genic regions. Share Price Performance The stock has outperformed its industry in the past year. It has gained 0.3% compared with the industry’s 31.3% fall. Zacks Rank and Key Picks Currently, Illumina carries a Zacks Rank #3 (Hold). A few better-ranked stocks in the broader medical space that investors can consider are AMN Healthcare Services, Inc. AMN , Apollo Endosurgery, Inc. APEN and Patterson Companies, Inc. PDCO . AMN Healthcare, carrying a Zacks Rank #1 (Strong Buy), has a long-term earnings growth rate of 16.2%. The company’s earnings surpassed estimates in the trailing four quarters, delivering a surprise of 19.5%, on average. AMN Healthcare has outperformed its industry over the past year. AMN has gained 48.3% against the 57.3% industry decline. Apollo Endosurgery, carrying a Zacks Rank #2 (Buy), has a long-term earnings growth rate of 7%. The company‘s earnings surpassed estimates in the trailing four quarters, delivering a surprise of 25.6%, on average. You can see the complete list of today’s Zacks #1 Rank stocks here. Apollo Endosurgery has outperformed its industry in the past year. APEN has gained 103.3% versus the industry’s 1% fall. Patterson Companies, sporting a Zacks Rank #2, has a long-term earnings growth rate of 9.9%. The company surpassed earnings estimates in three of the trailing four quarters and missed in one, delivering an average surprise of 3.7%. Patterson Companies has underperformed its industry over the past year. PDCO has declined 11.1% versus the industry’s 4.9% rise. Zacks’ Top Picks to Cash in on Artificial Intelligence This world-changing technology is projected to generate $100s of billions by 2025. From self-driving cars to consumer data analysis, people are relying on machines more than we ever have before. Now is the time to capitalize on the 4th Industrial Revolution. Zacks’ urgent special report reveals 6 AI picks investors need to know about today.

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing GRAIL

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

GRAIL is included in 6 Expert Collections, including Digital Health.

D

Digital Health

12,370 items

Startups recreating how healthcare is delivered

D

Digital Health 150

300 items

2019's cohort of the most promising digital health startups transforming the healthcare industry

C

Cancer

3,710 items

Products/services that analyze tumor-derived biomarkers (ctDNA, CTCs, exosomes) in blood/urine/other non-invasive liquid specimens to detect cancer earlier, guide treatment, and monitor progress. *Data fields manually updated as new information becomes available.'

M

Medical Devices

8,571 items

Companies developing medical devices (per the IMDRF's definition of "medical device"). Includes software, lab-developed tests (LDTs), and combination products. *Columns updated as regularly as possible.

H

Health Monitoring & Diagnostics

2,394 items

Companies developing or offering products that aid in the assessment, screening, diagnosis, or monitoring of a person's state of health/wellness. Excludes companies focused solely on fitness/sports performance

O

Omics

1,213 items

Companies involved in the capture, sequencing, and/or analysis of genomic, transcriptomic, proteomic, and/or metabolomic data

GRAIL Patents

GRAIL has filed 95 patents.

The 3 most popular patent topics include:

  • Molecular biology
  • DNA
  • Genetics
patents chart

Application Date

Grant Date

Title

Related Topics

Status

10/31/2018

11/23/2021

Molecular biology, DNA, Biotechnology, Genetics, Molecular biology techniques

Grant

Application Date

10/31/2018

Grant Date

11/23/2021

Title

Related Topics

Molecular biology, DNA, Biotechnology, Genetics, Molecular biology techniques

Status

Grant

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.